Waters and Daiso Sign Marketing Agreement for Bulk Process Chromatography Media
Waters Corporation (Milford, MA) and Daiso Co., Ltd. (Osaka, Japan) have entered into a collaborative agreement to globally market and supply Daisogel bulk packing materials for process chromatography.
Waters Corporation (Milford, MA) and Daiso Co., Ltd. (Osaka, Japan) have entered into a collaborative agreement to globally market and supply Daisogel bulk packing materials for process chromatography. The combined purification expertise of both organizations will aid pharmaceutical and biopharmaceutical companies as they move from laboratory-scale purifications into pilot-plant and process-scale manufacturing.
To simplify scaling-up purification methods, Daisogel columns are packed using Waters’ patented optimum bed density (OBD) technology. OBD technology enables analytical column performance and lifetime in larger preparative columns. The columns are designed to save time by eliminating the need for subsequent method redevelopment when the columns are scaled up.
Daiso’s comprehensive quality control system is based on ISO 9001 and has met the quality requirements of global pharmaceutical companies. Daiso also has a drug master file on file with the US Food and Drug Administration for the Daisogel packing materials. Daisogel packing materials and packed HPLC columns are available from Waters.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
